Published in Arthritis Res Ther on February 23, 2009
Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis | NCT00443430
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis | NCT00095173
Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res (2011) 1.06
Advances and challenges in imaging in juvenile idiopathic arthritis. Nat Rev Rheumatol (2012) 0.96
Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol (2011) 0.96
Assessment of cardiac and pulmonary function in children with juvenile idiopathic arthritis. Rheumatol Int (2010) 0.93
Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr (2010) 0.88
Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol (2010) 0.87
Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J (2016) 0.87
Current medical treatments for juvenile idiopathic arthritis. Front Pharmacol (2011) 0.86
Relationship between disease course in the temporomandibular joints and mandibular growth rotation in patients with juvenile idiopathic arthritis followed from childhood to adulthood. Pediatr Rheumatol Online J (2010) 0.83
Understanding treatment decision making in juvenile idiopathic arthritis: a qualitative assessment. Pediatr Rheumatol Online J (2013) 0.83
Using registries to identify adverse events in rheumatic diseases. Pediatrics (2013) 0.83
Juvenile idiopathic arthritis: management and therapeutic options. Ther Adv Musculoskelet Dis (2012) 0.83
Identification, frequency, activation and function of CD4+ CD25(high)FoxP3+ regulatory T cells in children with juvenile idiopathic arthritis. Rheumatol Int (2011) 0.81
QT dispersion and cardiac involvement in patients with juvenile idiopathic arthritis. Rheumatol Int (2011) 0.80
Intravenous laser blood irradiation increases efficacy of etanercept in selected subtypes of juvenile idiopathic arthritis: an innovative clinical research approach. Evid Based Complement Alternat Med (2013) 0.79
P wave dispersion in juvenile idiopathic arthritis patients with diastolic dysfunction. Iran J Pediatr (2012) 0.77
TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications? Int J Rheumatol (2012) 0.77
A Systematic Critical Appraisal of Clinical Practice Guidelines in Juvenile Idiopathic Arthritis Using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) Instrument. PLoS One (2015) 0.76
Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Turk J Ophthalmol (2016) 0.76
Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. Case Rep Rheumatol (2013) 0.76
Physician assessment of disease activity in JIA subtypes. Analysis of data extracted from electronic medical records. Pediatr Rheumatol Online J (2011) 0.76
Ultrasonographic assessment reveals detailed distribution of synovial inflammation in Blau syndrome. Arthritis Res Ther (2014) 0.75
The joints in juvenile idiopathic arthritis. Insights Imaging (2015) 0.75
A successful treatment of juvenile idiopathic arthritis with rituximab: A report of two cases. Eur J Rheumatol (2014) 0.75
Implementation of musculoskeletal ultrasonography in detection of early juvenile idiopathic arthritis. Eur J Radiol Open (2016) 0.75
Assessment of left atrial mechanical functions and atrial electromechanical delay in Juvenile idiopathic arthritis by tissue Doppler echocardiography. Pediatr Rheumatol Online J (2016) 0.75
Tumor necrosis factor-α -308 A/G gene polymorphism in children with juvenile idiopathic arthritis: relation to disease activity, damage, and functional status. Clin Rheumatol (2017) 0.75
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol (2004) 14.06
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum (1997) 5.57
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med (2005) 4.79
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med (2000) 4.76
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2007) 3.32
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol (2004) 2.91
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis (2007) 2.75
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum (2008) 2.56
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2008) 2.08
Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) (2002) 2.02
Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol (2008) 1.87
Medical treatment of juvenile idiopathic arthritis. JAMA (2005) 1.86
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis (2008) 1.78
Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr (2007) 1.75
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis (2008) 1.63
Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum (2005) 1.56
Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis (2007) 1.55
Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) (2008) 1.48
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood (2005) 1.37
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis (2006) 1.34
Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2006) 1.34
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol (2008) 1.29
Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma (2008) 1.26
Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med (2005) 1.22
Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol (2002) 1.18
Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol (2000) 1.14
Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12
Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer (2008) 1.09
Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum (2007) 1.04
Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol (1998) 1.03
Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol (2001) 1.03
Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis (2004) 0.98
Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis (2007) 0.95
Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) (2006) 0.94
Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol (2006) 0.94
Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol (2007) 0.92
Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine (2007) 0.86
Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis (2007) 0.86
Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr (2004) 0.85
The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. Cytokine (2008) 0.84
Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. Br J Clin Pharmacol (2005) 0.78
Leflunomide: long-term clinical experience and new uses. Expert Opin Pharmacother (2005) 0.77
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum (2008) 2.56
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum (2004) 2.31
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2012) 2.21
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2012) 1.84
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 1.51
Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. Pediatr Crit Care Med (2011) 1.51
Developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology (Oxford) (2010) 1.51
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum (2003) 1.42
Old challenges and new directions in pediatric rheumatology. J Rheumatol (2006) 1.40
An i2b2-based, generalizable, open source, self-scaling chronic disease registry. J Am Med Inform Assoc (2012) 1.39
Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2012) 1.33
Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken) (2010) 1.32
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2006) 1.16
Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum (2013) 1.13
Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) (2009) 1.10
Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum (2008) 1.09
Monitoring the long-term safety of therapies for children with juvenile idiopathic arthritis: time for a consolidated patient registry. Arthritis Care Res (Hoboken) (2010) 1.06
Polysomnography and self-reported sleep, pain, fatigue, and anxiety in children with active and inactive juvenile rheumatoid arthritis. J Pediatr Psychol (2007) 1.06
Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J (2010) 1.03
Sleep disturbance, daytime sleepiness, and neurocognitive performance in children with juvenile idiopathic arthritis. Sleep (2010) 1.01
Health-related quality of life, physical function, fatigue, and disease activity in children with established polyarticular juvenile idiopathic arthritis. J Rheumatol (2009) 1.00
Gene expression profiling in neutrophils from children with polyarticular juvenile idiopathic arthritis. Arthritis Rheum (2009) 1.00
Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum (2012) 0.98
Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis (2012) 0.97
Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol (2008) 0.95
Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2013) 0.95
Susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci. Arthritis Rheum (2013) 0.93
Measuring clinical response and remission in juvenile idiopathic arthritis. Curr Opin Rheumatol (2007) 0.92
Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. Arthritis Care Res (Hoboken) (2010) 0.90
Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken) (2014) 0.88
Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 0.87
Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum (2004) 0.86
Remission in juvenile idiopathic arthritis: current facts. Curr Rheumatol Rep (2010) 0.86
Heterotopic ossification of the temporomandibular joint in juvenile idiopathic arthritis. J Rheumatol (2011) 0.85
Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum (2010) 0.85
Disease activity and fatigue in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2013) 0.85
Evolution of paediatric-specific vasculitis classification criteria. Ann Rheum Dis (2010) 0.83
Using registries to identify adverse events in rheumatic diseases. Pediatrics (2013) 0.83
Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol Online J (2012) 0.82
Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs (2010) 0.82
Sleep disturbances and neurobehavioral functioning in children with and without juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) (2011) 0.81
Juvenile idiopathic arthritis in relation to maternal prenatal smoking. Arthritis Care Res (Hoboken) (2015) 0.80
Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol (2015) 0.79
Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. Arthritis Care Res (Hoboken) (2015) 0.77
Characterisation of gamma delta (γδ) T cell populations in patients with sepsis. Cell Biol Int (2014) 0.77
Injectable tumor necrosis factor α inhibitors and outpatient antimicrobial use in children with rheumatic diseases: analyses of prescription claims from a pharmacy benefit manager database. Arthritis Care Res (Hoboken) (2013) 0.77
Perinatal exposures and Kawasaki disease in Washington State: a population-based, case-control study. Pediatr Infect Dis J (2012) 0.77
HACCP-based food safety management systems: great in theory but can we really make them work in practice? Perspect Public Health (2014) 0.75
The food safety impact of salt and sodium reduction initiatives. Perspect Public Health (2014) 0.75
Methotrexate and injectable tumor necrosis factor-α inhibitor adherence and persistence in children with rheumatic diseases. J Rheumatol (2012) 0.75
Developing women leaders in medicine at the grass roots level: evolution from skills training to institutional change. J Pediatr (2007) 0.75